WallStreetZenWallStreetZen

NASDAQ: CRNX
Crinetics Pharmaceuticals Inc Stock

$40.47+1.80 (+4.65%)
Updated Feb 27, 2024
Crinetics Pharmaceuticals shares are trading... find out Why CRNX Price Moved with a free WallStreetZen account
Why Price Moved
CRNX Price
$40.47
Fair Value Price
-$3.85
Market Cap
$2.70B
52 Week Low
$15.23
52 Week High
$40.79
P/E
-11.15x
P/B
4.94x
P/S
357.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.72M
Earnings
-$199.42M
Gross Margin
100%
Operating Margin
-4,223.27%
Profit Margin
-4,223.3%
Debt to Equity
0.17
Operating Cash Flow
-$163M
Beta
1.15
Next Earnings
Feb 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CRNX Overview

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRNX ($40.47) is overvalued by 1,150.22% relative to our estimate of its Fair Value price of -$3.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRNX ($40.47) is not significantly undervalued (1,150.22%) relative to our estimate of its Fair Value price of -$3.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRNX due diligence checks available for Premium users.

Be the first to know about important CRNX news, forecast changes, insider trades & much more!

CRNX News

Valuation

CRNX fair value

Fair Value of CRNX stock based on Discounted Cash Flow (DCF)
Price
$40.47
Fair Value
-$3.85
Undervalued by
1,150.22%
CRNX ($40.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRNX ($40.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRNX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-11.15x
Industry
14.95x
Market
36.02x

CRNX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.94x
Industry
6.23x
CRNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRNX's financial health

Profit margin

Revenue
$346.0k
Net Income
-$57.5M
Profit Margin
-16,606.4%
CRNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$641.5M
Liabilities
$93.8M
Debt to equity
0.17
CRNX's short-term assets ($575.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRNX's short-term assets ($575.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$41.3M
Investing
-$193.3M
Financing
$337.9M
CRNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRNX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CRNX$2.70B+4.65%-11.15x4.94x
RYTM$2.72B-0.26%-14.21x13.78x
KYMR$2.66B+0.30%-17.29x6.74x
RCKT$2.77B+3.19%-9.64x5.12x
MRUS$2.83B+2.82%-13.02x7.18x

Crinetics Pharmaceuticals Stock FAQ

What is Crinetics Pharmaceuticals's quote symbol?

(NASDAQ: CRNX) Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol CRNX. Crinetics Pharmaceuticals stock quotes can also be displayed as NASDAQ: CRNX.

If you're new to stock investing, here's how to buy Crinetics Pharmaceuticals stock.

What is the 52 week high and low for Crinetics Pharmaceuticals (NASDAQ: CRNX)?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's 52-week high was $40.79, and its 52-week low was $15.23. It is currently -0.78% from its 52-week high and 165.73% from its 52-week low.

How much is Crinetics Pharmaceuticals stock worth today?

(NASDAQ: CRNX) Crinetics Pharmaceuticals currently has 66,799,257 outstanding shares. With Crinetics Pharmaceuticals stock trading at $40.47 per share, the total value of Crinetics Pharmaceuticals stock (market capitalization) is $2.70B.

Crinetics Pharmaceuticals stock was originally listed at a price of $24.51 in Jul 18, 2018. If you had invested in Crinetics Pharmaceuticals stock at $24.51, your return over the last 5 years would have been 65.12%, for an annualized return of 10.55% (not including any dividends or dividend reinvestments).

How much is Crinetics Pharmaceuticals's stock price per share?

(NASDAQ: CRNX) Crinetics Pharmaceuticals stock price per share is $40.47 today (as of Feb 27, 2024).

What is Crinetics Pharmaceuticals's Market Cap?

(NASDAQ: CRNX) Crinetics Pharmaceuticals's market cap is $2.70B, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Crinetics Pharmaceuticals's market cap is calculated by multiplying CRNX's current stock price of $40.47 by CRNX's total outstanding shares of 66,799,257.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.